Dr. Martens Valuation

Q: What is the Fair Price of DOCS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DOCS (£0.59) is trading below our estimate of [[fair value]] (£0.93)

Is DOCS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DOCS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DOCS (£0.59) is trading below our estimate of fair value (£0.93)

Significantly Below Fair Value: DOCS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DOCS?

Key metric: As DOCS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DOCS. This is calculated by dividing DOCS's market cap by their current earnings.
What is DOCS's PE Ratio?
PE Ratio	8.1x
Earnings	UK£69.20m
Market Cap	UK£559.55m

DOCS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	6.5x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does DOCS's PE Ratio compare to its peers?

The above table shows the PE ratio for DOCS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	36.9x
COA Coats Group	19.3x	17.8%	UK£1.5b
GLE MJ Gleeson	16.4x	15.0%	UK£315.8m
BOOT Henry Boot	27x	25.5%	UK£303.4m
BRBY Burberry Group	85.1x	37.2%	UK£3.2b
DOCS Dr. Martens	8.1x	5.7%	UK£559.6m

Price-To-Earnings vs Peers: DOCS is good value based on its Price-To-Earnings Ratio (8.1x) compared to the peer average (36.9x).

Price to Earnings Ratio vs Industry

How does DOCS's PE Ratio compare vs other companies in the European Luxury Industry?

4 Companies	Price / Earnings	Estimated Growth	Market Cap

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: DOCS is good value based on its Price-To-Earnings Ratio (8.1x) compared to the European Luxury industry average (14.2x).

Price to Earnings Ratio vs Fair Ratio

What is DOCS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DOCS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	8.1x
Fair PE Ratio	13.4x

Price-To-Earnings vs Fair Ratio: DOCS is good value based on its Price-To-Earnings Ratio (8.1x) compared to the estimated Fair Price-To-Earnings Ratio (13.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DOCS forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	UK£0.59	UK£0.76 +28.9%	14.0%	UK£0.95	UK£0.60	n/a	8
Nov ’25	UK£0.56	UK£0.76 +36.8%	12.9%	UK£0.95	UK£0.60	n/a	8
Oct ’25	UK£0.56	UK£0.78 +39.6%	10.5%	UK£0.95	UK£0.70	n/a	8
Sep ’25	UK£0.72	UK£0.78 +7.9%	10.5%	UK£0.95	UK£0.70	n/a	8
Aug ’25	UK£0.70	UK£0.78 +11.3%	10.7%	UK£0.95	UK£0.70	n/a	8
Jul ’25	UK£0.74	UK£0.77 +4.6%	10.7%	UK£0.95	UK£0.70	n/a	8
Jun ’25	UK£0.87	UK£0.75 -14.2%	11.6%	UK£0.95	UK£0.65	n/a	8
May ’25	UK£0.77	UK£0.77 -0.1%	18.6%	UK£1.10	UK£0.65	n/a	8
Apr ’25	UK£0.88	UK£0.96 +9.1%	10.9%	UK£1.10	UK£0.85	n/a	9
Mar ’25	UK£0.97	UK£0.98 +1.4%	9.4%	UK£1.10	UK£0.85	n/a	9
Feb ’25	UK£0.85	UK£0.98 +15.1%	9.4%	UK£1.10	UK£0.85	n/a	9
Jan ’25	UK£0.89	UK£1.22 +37.8%	16.8%	UK£1.60	UK£1.00	n/a	9
Dec ’24	UK£0.95	UK£1.35 +41.8%	12.3%	UK£1.60	UK£1.10	n/a	9
Nov ’24	UK£1.18	UK£1.59 +35.1%	14.2%	UK£2.15	UK£1.40	UK£0.56	9
Oct ’24	UK£1.41	UK£1.59 +12.4%	14.2%	UK£2.15	UK£1.40	UK£0.56	9
Sep ’24	UK£1.57	UK£1.59 +1.5%	14.2%	UK£2.15	UK£1.40	UK£0.72	9
Aug ’24	UK£1.44	UK£1.59 +10.2%	14.2%	UK£2.15	UK£1.40	UK£0.70	9
Jul ’24	UK£1.22	UK£1.64 +34.0%	16.9%	UK£2.15	UK£1.40	UK£0.74	9
Jun ’24	UK£1.38	UK£1.92 +39.1%	15.4%	UK£2.50	UK£1.52	UK£0.87	9
May ’24	UK£1.66	UK£2.04 +22.8%	19.2%	UK£2.72	UK£1.52	UK£0.77	9
Apr ’24	UK£1.42	UK£2.08 +46.3%	24.6%	UK£3.00	UK£1.40	UK£0.88	8
Mar ’24	UK£1.56	UK£2.11 +35.8%	22.0%	UK£3.00	UK£1.40	UK£0.97	9
Feb ’24	UK£1.58	UK£2.54 +60.6%	30.9%	UK£4.00	UK£1.40	UK£0.85	8
Jan ’24	UK£1.91	UK£3.35 +75.8%	22.4%	UK£5.00	UK£2.50	UK£0.89	8
Dec ’23	UK£2.11	UK£3.52 +67.1%	24.6%	UK£5.00	UK£2.50	UK£0.95	8
Nov ’23	UK£2.50	UK£3.83 +53.1%	20.4%	UK£5.50	UK£2.76	UK£1.18	8

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.